Gordon Leo I
Division of Hematology/Oncology, Feinberg School of Medicine, and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA.
Semin Oncol. 2003 Dec;30(6 Suppl 17):23-8. doi: 10.1053/j.seminoncol.2003.10.003.
90Y ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA), the first radioimmunotherapeutic agent approved by the US Food and Drug Administration, is a promising treatment option in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with rituximab-refractory follicular non-Hodgkin's lymphoma. The ibritumomab tiuxetan regimen is administered on an outpatient basis over approximately 1 week and with the simplicity of weight-based dosing (ie, calculation of whole body clearance is unnecessary). Other than acrylic shielding, only universal precautions are required to administer (90)Y ibritumomab tiuxetan, and patient isolation is unnecessary. This treatment regimen requires a coordinated multidisciplinary approach. Oncologists play a leading role in selecting patients for (90)Y ibritumomab tiuxetan therapy and in prescribing and overseeing the treatment.
90钇替伊莫单抗（泽瓦林；百健艾迪公司，马萨诸塞州剑桥）是美国食品药品监督管理局批准的首个放射免疫治疗药物，对于复发或难治性低度、滤泡性或转化型B细胞非霍奇金淋巴瘤患者，包括对利妥昔单抗难治的滤泡性非霍奇金淋巴瘤患者而言，它是一种很有前景的治疗选择。钇替伊莫单抗治疗方案在门诊进行，疗程约1周，且基于体重给药简单（即无需计算全身清除率）。除丙烯酸屏蔽外，给予90钇替伊莫单抗仅需采取通用防护措施，无需对患者进行隔离。这种治疗方案需要多学科协作。肿瘤学家在选择钇替伊莫单抗治疗的患者以及开出处方和监督治疗方面发挥主导作用。
